PERSPECTA

News from every angle

← Back to headlines

Jazz Pharmaceuticals Forecasts 2026 Revenue, Awaits Zanidatamab PDUFA

Jazz Pharmaceuticals projects its 2026 revenue to be between $4.60 billion and $4.75 billion, as the company anticipates an August 25 PDUFA date for its drug zanidatamab.

4 Aug, 01:10 — 4 Aug, 01:10
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed2h ago

Jazz forecasts $4.60B-$4.75B 2026 revenue as it prepares for Aug. 25 zanidatamab PDUFA

Read full article →

Related Stories

South Korea to End Draft Beer Tax Break, Increasing Costs

14m ago

LG Uplus Acquires Pago Networks in First Security M&A Push

20m ago

FAA Certifies Boeing 737 MAX 7 After Years of Delays

21m ago

Companies Raise 2026 Revenue and FFO Guidance

21m ago